

Arthritis Relief Plus receives positive results from a trial comparing Acteev® to a placebo

15 September 2008, Gold Coast, Australia: Today Arthritis Relief Plus Limited (ARP) announced the results of a double blind, placebo controlled randomized trial conducted under the auspices of Oklahoma State University.

The purpose of this study was to determine the effect of 2 concentrations of Acteev® and to compare them to placebo ointment on pain, stiffness and physical functioning in subjects with primary osteoarthritis of the knee.

Thirty-three male and female subjects ranging in age from 45 to 83 years with primary osteoarthritis of the knee applied the topical ointments 3 times a day for 6 weeks. Outcomes were measured using the pain, stiffness and function subscales of the WOMAC osteoarthritis index.

Both concentrations of Acteev® were significantly superior to the placebo in reducing pain and stiffness and improving daily activities in those with primary osteoarthritis of the knee. On the primary outcome of change in the WOMAC pain subscale, the higher concentration Acteev® formula had a 21% greater change than the placebo. The lower concentration Acteev® formula had a 27% and 22% greater change in the WOMAC function and stiffness subscales in comparison to the placebo.

The results of the placebo study complements the positive results from a comparative study performed earlier in 2008 through Oklahoma State University further validating the efficacy of Acteev®.

ARP Director, Persis Anderson said “Now that osteoarthritis is considered a metabolically active, reparative process amenable to treatment, products such as Acteev® have great potential to make a positive difference to the lives of millions of people. These results get us one step closer to making Acteev® available to those people”.

Acteev® is a registered Trademark of Arthritis Relief Plus Ltd.

###

About Arthritis Relief Plus Ltd.

ARP is a Queensland based, unlisted public company. ARP owns the rights to commercialize Acteev®, a novel formulation that has patent protection pending. ARP is developing the commercial application of Acteev® in a variety of human and animal degenerative joint conditions including osteoarthritis, cervical and lumbar spondylitis. ARP’s lead product is for the treatment of osteoarthritis and may prove to be the world’s first natural and topical treatment providing long-term results with no known side effects.

Contact Information: Persis Anderson

Director, Arthritis Relief Plus Ltd

Phone: +1 310 929-5277

Email: info@arthritisreliefplus.com.au